About Hyperfine, Inc. - Class A Common Stock (HYPR)
Hyperfine, Inc. is a healthcare technology company that specializes in the development of mobile MRI systems. Their innovative approach aims to make magnetic resonance imaging more accessible and convenient, particularly in settings outside traditional imaging facilities, such as hospitals and clinics. By utilizing a portable and easy-to-use MRI device, the company enhances the ability of healthcare providers to perform rapid diagnostic imaging, ultimately improving patient care and outcomes. Hyperfine is dedicated to transforming the way medical imaging is delivered, focusing on affordability, portability, and ease of use for medical professionals. Read More
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans to present at the upcoming Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4th at 8:10 am Eastern Time (ET).
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the strengthening of the company’s initiatives to improve global brain health in underserved settings through a Gates Foundation grant of $3.7 million.
Hyperfine (HYPR) reported mixed Q3 2025 results, missing revenue and EPS estimates. The stock fell as its Q4 revenue guidance also trailed analyst expectations.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2025 financial results and provided a business update.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report full financial results for the third quarter 2025 on Thursday, November 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans for clinical use expansion into the operating room environment, advancing its mission to make brain MRI more accessible across a diversity of care settings. The company plans to establish a foothold in the neurosurgical operating setting by launching a new study to build a body of clinical evidence for Swoop® system use in neurosurgical procedures.
Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced it has priced its previously announced underwritten public offering of 14,000,000 shares of the Company’s Class A common stock at a public offering price of $1.25 per share. All of the shares in the offering are being sold by Hyperfine. In addition, Hyperfine has granted the underwriter a 30-day option to purchase up to 2,100,000 shares of Class A common stock, which equals 15% of the total number of shares of Class A common stock to be sold in the offering, at the public offering price, less underwriting discounts and commissions. The gross proceeds to Hyperfine from the offering are expected to be approximately $17.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Hyperfine. The offering is expected to close on or about October 17, 2025, subject to the satisfaction of customary closing conditions.
Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of securities sold in the offering (consisting of shares of Class A common stock, pre-funded warrants or any combination thereof), on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited financial results for the third quarter ended September 30, 2025.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that its distribution partner, UpCare Europe SAS (UpCare), has been awarded a national referencing for the Swoop® system by UniHA (Union des Hôpitaux pour les Achats), France’s leading public healthcare purchasing cooperative.
